PDF(Pubmed)
Abstract：
Cardiometabolic diseases (CMDs) are the major types of non-communicable diseases, contributing to huge disease burdens in the Western Pacific region (WPR). The use of digital health (dHealth) technologies, such as wearable gadgets, mobile apps, and artificial intelligence (AI), facilitates interventions for CMDs prevention and treatment. Currently, most studies on dHealth and CMDs in WPR were conducted in a few high- and middle-income countries like Australia, China, Japan, the Republic of Korea, and New Zealand. Evidence indicated that dHealth services promoted early prevention by behavior interventions, and AI-based innovation brought automated diagnosis and clinical decision-support. dHealth brought facilitators for the doctor-patient interplay in the effectiveness, experience, and communication skills during healthcare services, with rapidly development during the pandemic of coronavirus disease 2019. In the future, the improvement of dHealth services in WPR needs to gain more policy support, enhance technology innovation and privacy protection, and perform cost-effectiveness research.
摘要：
心脏代谢疾病（CMD）是非传染性疾病的主要类型，导致西太平洋地区（WPR）的巨大疾病负担。使用数字健康（dHealth）技术，例如可穿戴小工具，移动应用程序，和人工智能(AI)，促进CMD预防和治疗的干预措施。目前,WPR中关于dHealth和CMD的大多数研究是在澳大利亚等几个高收入和中等收入国家进行的，中国,Japan,大韩民国,和新西兰。证据表明，医疗服务通过行为干预促进早期预防，基于AI的创新带来了自动化诊断和临床决策支持。dHealth为医患互动带来了促进者，经验,以及医疗保健服务期间的沟通技巧，在2019年冠状病毒疾病大流行期间迅速发展。在未来,WPR医疗服务的改善需要获得更多的政策支持，加强技术创新和隐私保护，并进行成本效益研究。
